Clinical application of the anti-human telomerase reverse transcriptase (hTERT) antibody (SCD-A7) immunocytochemistry in liquid-based urine cytology: A prospective, single institute study.
biomarker
cytology
immunocytochemistry
telomerase reverse transcriptase
urine
urothelial carcinoma
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
16
02
2023
received:
18
11
2022
accepted:
22
02
2023
medline:
30
5
2023
pubmed:
15
3
2023
entrez:
14
3
2023
Statut:
ppublish
Résumé
Urine cytology is the most widely used noninvasive screening tool for urothelial carcinoma diagnosis and surveillance. Although highly specific, urine cytology exhibits suboptimal sensitivity. This study aimed to determine whether hTERT immunocytochemistry (ICC) could be applicable as an ancillary test in routine cytology practice. A total of 561 urinary tract samples were initially screened in this study. All of them were prepared using SurePath liquid-based cytology (LBC), while additional LBC slides were made and subsequently used for hTERT (SCD-A7) ICC. From the 561 samples screened, 337 were finally analyzed, all having an adequate cellularity and available follow-up histology. The hTERT ICC-positive rate was 95.9% (n = 208/217), 96% (n = 24/25), and 100% (n = 4/4) in cytology samples with high-grade urothelial carcinoma, carcinoma in situ, and low-grade urothelial carcinoma subsequent histology. Among the 64 atypical cytology cases histologically confirmed as urothelial carcinomas, 92.2% (n = 59/64) were immunoreactive to hTERT, whereas the two histologically benign cases were ICC-negative. 87/90 (96.7%) of the cytology cases confirmed to be benign in follow-up were hTERT-negative. The overall sensitivity and specificity of hTERT ICC were 96.3% and 98.8%, respectively (AUROC = 0.963; 95% CI = 0.960-0.967). The hTERT ICC test exhibited consistent and intense staining in malignant urothelial cells, suggesting its value as an ancillary test in liquid-based urine cytology.
Identifiants
pubmed: 36916414
doi: 10.1002/cam4.5767
pmc: PMC10225183
doi:
Substances chimiques
Telomerase
EC 2.7.7.49
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10363-10370Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Science. 2013 Feb 22;339(6122):957-9
pubmed: 23348506
EBioMedicine. 2020 Mar;53:102643
pubmed: 32081602
Cancer Cytopathol. 2013 Jul;121(7):387-91
pubmed: 23536358
Urol Oncol. 2020 Mar;38(3):77.e17-77.e25
pubmed: 31521529
Science. 1994 Dec 23;266(5193):2011-5
pubmed: 7605428
Urol Oncol. 2021 Jan;39(1):41-51
pubmed: 32919875
Hum Pathol. 2011 Apr;42(4):455-81
pubmed: 21106220
Cytopathology. 2016 Apr;27(2):83-90
pubmed: 25580773
Cancers (Basel). 2021 Mar 10;13(6):
pubmed: 33802026
Br J Cancer. 2017 Aug 8;117(4):583-587
pubmed: 28683471
J Urol. 2006 Dec;176(6 Pt 1):2343-6
pubmed: 17085097
Microbiol Mol Biol Rev. 2002 Sep;66(3):407-25, table of contents
pubmed: 12208997
BJU Int. 2006 May;97(5):997-1001
pubmed: 16542342
Mol Cancer Ther. 2010 Feb;9(2):257-67
pubmed: 20124458
Urol Ann. 2010 Sep;2(3):100-6
pubmed: 20981196
Cytopathology. 2016 Dec;27(6):456-464
pubmed: 27873391
Diagn Cytopathol. 2012 Sep;40(9):755-9
pubmed: 22888081
BMC Urol. 2021 Apr 19;21(1):64
pubmed: 33874920
Cancer Med. 2023 May;12(9):10363-10370
pubmed: 36916414
Cancer. 2005 Dec 25;105(6):468-75
pubmed: 16080177
Acta Cytol. 2018;62(4):302-310
pubmed: 29874657
Acta Cytol. 1993 Mar-Apr;37(2):163-9
pubmed: 8465635
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
J Am Soc Cytopathol. 2021 Jan-Feb;10(1):88-93
pubmed: 32354607
Mol Oncol. 2013 Jun;7(3):704-18
pubmed: 23562353
BJU Int. 2002 Mar;89(4):369-73
pubmed: 11872026
Urol Oncol. 2021 Aug;39(8):498.e21-498.e33
pubmed: 33676848